Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Kura Oncology (KURA) Equity Average (2023 - 2026)

Kura Oncology has reported Equity Average over the past 4 years, most recently at $141.0 million for Q1 2026.

  • Quarterly Equity Average fell 63.75% to $141.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $141.0 million through Mar 2026, down 63.75% year-over-year, with the annual reading at $293.9 million for FY2025, 27.52% down from the prior year.
  • Equity Average was $141.0 million for Q1 2026 at Kura Oncology, down from $208.3 million in the prior quarter.
  • Over five years, Equity Average peaked at $485.6 million in Q2 2024 and troughed at $141.0 million in Q1 2026.
  • The 4-year median for Equity Average is $413.6 million (2023), against an average of $372.4 million.
  • Year-over-year, Equity Average rose 13.6% in 2024 and then plummeted 63.75% in 2026.
  • A 4-year view of Equity Average shows it stood at $413.6 million in 2023, then increased by 1.23% to $418.7 million in 2024, then crashed by 50.24% to $208.3 million in 2025, then crashed by 32.32% to $141.0 million in 2026.
  • Per Business Quant, the three most recent readings for KURA's Equity Average are $141.0 million (Q1 2026), $208.3 million (Q4 2025), and $274.0 million (Q3 2025).